Universita' Degli Studi Di Napoli Federico II — Clinical Trial Site

19 Registered trials

11 Currently recruiting

Organisation

Universita' Degli Studi Di Napoli Federico II

Location

Naples, Italy

Identifier

ORG-100010463

Address

Via Sergio Pansini 6 Ed 17, 80138, Italy

Departments

#8002:Ematologia
Cardiologia
Department of Clinical Medicine and Surgery University of Naples “Federico II”
Dipartimento di Medicina Clinica e Chirurgia
Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia
Dipartimento di Pediatria
Dipartimento di Sanità Pubblica
Gastroenterologia ed Endoscopia Digestiva
Interdepartmental Center of Research in Immunological Science
Medical Oncology
Medicina E Chirurgia Università Degli Studi di Napoli - Federico II
Oncologia Medica
Scienze Mediche Traslazionali
U.O.C. Ematologia e Trapianti di Midollo
U.O.C. Oncologia Medica
UO Nefrologia
UOC Ematologia con TMO

Clinical trials at this site (19)

Search interface

A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting

2023-507555-29-00 LA/mGC/GEJC (locally advanced unresectable or metastati 9 2024-08-16
An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting

2023-505766-28-00 Hereditary angioedema 10 2022-10-10
Atacicept in Multiple Glomerular Diseases Recruiting

2024-518465-10-00 Multiple Autoimmune Glomerular Diseases 4 2025-12-12
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met… Recruiting

2024-519322-20-00 metastatic colorectal cancer 5 2025-07-21
A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting

2024-515526-89-00 Diffuse Large B-Cell Lymphoma (DLBCL) 4 2025-05-16
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive br… Recruiting

2024-519514-31-00 metastatic triple-negative PD-L1 positive breast cancer 4 2025-01-31
A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in… Recruiting

2023-508949-40-00 Eosinophilic esophagitis 4 2024-11-29
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… Recruiting

2024-510690-16-00 Relapsed/refractory follicular lymphoma 5 2022-01-31
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended

2023-506525-11-00 Primary Membranous Nephropathy (pMN) 5 2021-04-19
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended

2022-503073-11-00 Stage IIIb cardiac AL amyloidosis 5 2021-02-13
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects … Ended

2023-505170-15-00 Adult Subjects With Late Onset Pompe Disease (LOPD) 5 2020-05-15
A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa… Ended

2023-508377-82-00 Hidradenitis Suppurativa (HS) 10 2024-06-27
Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial hypertension… Ended

2023-509695-42-00 Pulmonary vascular disease 4 2022-07-25
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended

2024-514515-10-00 Breast Cancer 5 2016-06-16
Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men Ended

2024-518159-52-02 Hypogonadotropic hypogonadism 10